2.mesenchymal stem cells and osteogenesis.
Cho Rok JUNG ; Kondabagil R KIRAN ; Byoung S KWON
Immune Network 2001;1(3):179-186
No abstract available.
Mesenchymal Stromal Cells*
;
Osteogenesis*
3.Study on the simplifying antibody cocktail technique for isolation of human mesenchymal stromal cells (hMSCs).
Jung Hyun PARK ; Kyoung Hwa KIM ; Yong Moo LEE ; Young KU ; In Chul RHYU ; Soo Boo HAN ; Chong Pyoung CHUNG
The Journal of the Korean Academy of Periodontology 2004;34(1):93-100
No abstract available.
Humans*
;
Mesenchymal Stromal Cells*
4.Generation and characterisation of human umbilical cord derived mesenchymal stem cells by explant method
Zuraidah Yusoff ; Maryam Maqbool ; Elizabeth George ; Roshida Hassan ; Rajesh Ramasamy
The Medical Journal of Malaysia 2016;71(3):105-110
Mesenchymal stem cells (MSCs) derived from human
umbilical cord (UC) have been considered as an important
tool for treating various malignancies, tissue repair and
organ regeneration. Umbilical cord-derived mesenchymal
stem cells (UC-MSCs) are better alternative to MSCs that
derived from bone marrow (BM-MSCs) as they are regarded
as medical waste with little ethical concern for research and
easily culture-expanded. In this present study, the foetal
distal end of human UC was utilised to generate MSC by
explant method. Upon in vitro culture, adherent cells with
fibroblastic morphology were generated with rapid growth
kinetics. Under the respective inductive conditions, these
cells were capable of differentiating into adipocytes and
osteocytes; express an array of standard MSC’s surface
markers CD29, CD73, CD90, CD106 and MHC-class I. Further
assessment of immunosuppression activity revealed that
MSCs generated from UC had profoundly inhibited the
proliferation of mitogen-activated T lymphocytes in a dosedependent
manner. The current laboratory findings have
reinforced the application of explant method to generate UCMSCs
thus, exploring an ideal platform to fulfil the
increasing demand of MSCs for research and potential
clinical use.
Mesenchymal Stromal Cells
5.Basic Fibroblast Growth Factor Enhances the Expansion and Secretory Profile of Human Placenta-Derived Mesenchymal Stem Cells
Shalini Vellasamy ; Sharmili Vidyadaran ; Elizabeth George ; Rajesh Ramasamy
Malaysian Journal of Medicine and Health Sciences 2016;12(1):49-59
Introduction:Mesenchymal stem cells (MSCs) hold a great therapeutic potential for regenerative
medicine and tissue engineering due to inherent immunomodulatory and reparative properties. Hence,
it necessitates a readily available supplyof MSCs to meet the clinical demands adequately. Although,
a human placenta can produce MSCs, the in vitro culture-mediated cellular senescence often affect the
quality of cell product. Thus, the current study has explored the feasibility of basic fibroblast growth
factor (bFGF) to enhance the growth of placenta-derived MSCs (PLC-MSCs). Methods:The basic
fibroblast growth factor (bFGF) was supplemented to optimise the growth of MSCs. The effects of
bFGF on morphology, growth kinetics and cytokine secretion of PLC-MSCs were assessed. Results:
The bFGF supplementation increased the proliferation of PLC-MSCs in a dose-dependent manner and
40 ng/ml showed a high trophism effect on PLC-MSC’s growth. In the presence of bFGF, PLC-MSCs
acquired a small and well-defined morphology that reflect an active proliferative status. BFGF has
induced PLC-MSCs to achieve a shorter doubling time (45 hrs) as compared to the non-supplemented
PLC-MSCs culture (81 hrs). Furthermore, bFGF impelled PLC-MSCs into cell cycle machinery where
a substantial fraction of cells was driven to S and G2/M phases. Amongst, 36 screened cytokines, bFGF
had only altered the secretion of IL-8, IL-6, TNFR1, MMP3 and VEGF. Conclusion:The present study
showed that bFGF supplementation promotes the growth of PLC-MSCs without significantly deviating
from the standard criteria of MSCs. Thus, bFGF could be considered as a potential mitogen to facilitate
the large-scale production of PLC-MSCs.
Mesenchymal Stromal Cells
6.Letter: The advantages and limitations of mesenchymal stem cells in clinical application for treating human diseases
Osteoporosis and Sarcopenia 2018;4(4):150-150
No abstract available.
Humans
;
Mesenchymal Stromal Cells
7.Suppression of inflammatory damage to the brain after global cerebral ischemia by transplanted mesenchymal stem cells via secretion of TSG-6
Qingming Lin ; Shirong Lin ; Yisong Lv ; Lili Zhou ; Yue Fu ; Xiangshao Fang ; Feng Chen ; Zitong Huang
Neurology Asia 2016;21(2):113-122
Objective: Numerous studies have shown that bone marrow-derived mesenchymal stem cells
(MSCs) enhance neurological recovery after cerebral ischemia. However, the mechanisms are still
not clear. The present study aimed to investigate the beneficial effects of MSCs on global cerebral
ischemia induced by cardiac arrest (CA) and the underlying mechanisms. Methods: Rats subjected to
asphyxial CA were injected intravenously with MSCs (5×106
) at 2 hours after resuscitation. Whole
brain histopathologic damage scores (HDS) were assessed by histopathology at 3 and 7 days after
resuscitation. The distribution of donor MSCs in the brain was evaluated. The expression of tumor
necrosis factor-α-induced protein 6 (TSG-6) and pro-inflammatory cytokines in cerebral cortex was
assayed. After intravenous infusion of TSG-6 siRNA-MSCs, HDS and pro-inflammatory cytokines
were reevaluated at 7 days after resuscitation. Results: Intravenously administered MSCs significantly
reduced whole brain HDS after global cerebral ischemia. Immunofluorescence microscopy revealed
that donor MSCs were primarily found in cerebral cortex and expressed TSG-6. MSCs treatment
significantly increased the expression of TSG-6 and reduced the expression of pro-inflammatory
cytokines in cerebral cortex. In addition, intravenous infusion of TSG-6 siRNA-MSCs failed to
attenuate brain inflammation. Conclusion: Systemically administered MSCs reduced inflammatory
damage to brain in rats with global cerebral ischemia via secretion of TSG-6.
Heart Arrest
;
Mesenchymal Stromal Cells
8.Adults Mesenchymal Stem Cells for Bone Tissue Engineering.
Journal of Korean Society of Endocrinology 2005;20(5):425-433
No abstract available.
Adult*
;
Bone and Bones*
;
Humans
;
Mesenchymal Stromal Cells*
9.Treatment of Articular Cartilage Injury Using Mesenchymal Stem Cells.
Sung Ryeoll PARK ; Seok Jung KIM
Journal of Korean Orthopaedic Research Society 2015;18(1):18-24
Articular cartilage lesions can be a debilitating disease resulting in the development of osteoarthritis (OA). In recent years, mesenchymal stem cell (MSC) strategies combined with the microfracture technique are emerging as a powerful tool for cartilage repair. Even though there are some successful reports of MSCs treatments, many aspects have to be optimized such as best cell source and application method. The interest in this field is growing and randomized controlled trials are needed to show the potential of MSC treatment.
Cartilage
;
Cartilage, Articular*
;
Mesenchymal Stromal Cells*
;
Osteoarthritis
10.Research advances on immunoregulation and anti-inflammation function of mesenchymal stem cells and their application in treatment of renal diseases.
Journal of Zhejiang University. Medical sciences 2014;43(3):372-378
Mesenchymal stem cell (MSC) can differentiate into multiple lines in various tissues. MSC has the advantage of congenital hypoimmunogenicity and can interact with both innate and adaptive immunocytes, exerting immunoregulatory function via direct cell-cell contact and secreting soluble factors. It also can migrate to tissue injury sites to dampen inflammatory reactions. MSC can be potentially applied to treat immunological and inflammatory diseases, such as acute renal injury, immune kidney diseases, diabetic nephropathy and end-stage renal diseases. This review summarizes the biological characteristics of MSC and the prospects of its application in treatment of renal diseases.
Humans
;
Kidney Diseases
;
Mesenchymal Stromal Cells
;
immunology